Nivolumab/Ipilimumab Combination Data Promising In Msi-H/Dmmr Mcrc

Nivolumab/Ipilimumab Combination Data Promising in MSI-H/dMMR mCRC

Targeted Oncology

Promising CheckMate-142 Data for Second-Line Ipilimumab Plus Nivolumab in mCRC

Targeted Oncology

CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

Dr. Andre on Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC

Nivolumab and Ipilimumab Combination in Frontline mCRC

Targeted Oncology

Nivolumab plus low-dose ipilimumab promising for treatment-naïve MSI-high mCRC | Heinz-Josef Lenz

Medicine Matters oncology

KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRC

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

Dr. Lenz on Updated Data From CheckMate 142 With Nivolumab + Ipilimumab in mCRC

CheckMate 8HW: first-line nivolumab plus ipilimumab in MSI-H/dMMR mCRC

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC

Moving Forward With Results From CheckMate-142 in MSI-H mCRC

Targeted Oncology

I-O Therapy in mCRC: Ipilimumab + Nivolumab

RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab in MSI/dMMR mCRC

Remaining questions for the treatment of patients with MSI/dMMR mCRC with immunotherapy

CheckMate142: Checkpoint combination therapy in first-line colorectal cancer

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC